# A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

> **NCT07076121** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 470 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** BMS-986504
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07076121
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-23
- **Primary completion:** 2029-05-03
- **Final completion:** 2029-05-03
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07076121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07076121, "A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07076121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*